Infectious diseases: Coronavirus-Covid19 vaccine

One of the relevant features of BiOMViS’ technology is the rapidity with which OMV-based vaccine formulations can be produced and tested.
Soon after the sequence and the 3D structure of the SARS-CoV-2 spike protein had become available, BiOMViS generated a battery of engineered OMVs carrying selected SARS-CoV-2 protein fragments. The successful expression and accumulation of a number of these constructs in OMVs have been confirmed by sequence analysis of the gene constructs and by SDS-PAGE analysis of purified OMVs.
A number of engineered OMVs are currently under evaluation for their capacity to elicit antibodies capable of neutralizing pseudotype virus entry in ACE2-positive cells.The data currently available show that engineered OMVs can elicit neutralizing antibodies in the same range of what measured in sera from three patients.
BiOMViS’ objective is to bring the vaccine to development by end of Q3 2020 and is seeking partners interested to bring the vaccine to the clinics.